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To determine whether the rate of Clostridium difﬁ  cile–
associated disease (CDAD) and CDAD-related deaths 
were increasing in Finland, we analyzed registry data from 
1996 through 2004. We determined the number of hospi-
tal discharges that had a diagnosis code speciﬁ  c for CDAD 
from the International Classiﬁ  cation of Diseases, 10th revi-
sion: “enterocolitis due to Clostridium difﬁ  cile” (A04.7) and 
“pseudomembranous enterocolitis associated with anti-
microbial therapy” (K52.8), listed as any diagnosis in the 
National Hospital Discharge Registry. CDAD-related deaths 
were identiﬁ   ed from death certiﬁ  cates. Those  discharged 
with a CDAD diagnosis doubled from 810 (16/100,000 
population) in 1996 to 1,787 (34/100,000) in 2004. The in-
crease was most prominent for patients >64 years of age 
but concerned only those discharged with diagnosis code 
A04.7. The number of those discharged with diagnosis code 
K52.8 remained stable. The age-standardized mortality rate 
associated with CDAD increased from 9/million in 1998 to 
17/million in 2004; the increase was limited to persons >64 
years of age. 
T
oxin-producing Clostridium difﬁ  cile is the most fre-
quent cause of antimicrobial drug–associated diar-
rhea. The clinical spectrum of C. difﬁ  cile–associated 
disease (CDAD) ranges from mild diarrhea to severe life-
threatening pseudomembraneous enterocolitis. Several 
reports from hospitals in the United States, Canada, and 
Europe suggest that the incidence and severity of CDAD 
are increasing (1). This increase is assumed to be associ-
ated with higher toxin production by a ﬂ  uoroquinolone-
resistant strain belonging to pulsed-ﬁ  eld gel electropho-
resis type NAP1, PCR ribotype 027, and toxinotype III 
(2,3). However, the same virulence factors may also be 
present in other C. difﬁ  cile strains. Since 2003, PCR ribo-
type 027 has been detected in several European countries, 
including Finland in 2007 (4,5). Little information from 
nationwide, population-based studies on CDAD epidemi-
ology existed before the emergence of this strain.
Various methods and strategies are used to diagnose 
C. difﬁ  cile infection, which makes it difﬁ  cult to accurately 
compare the epidemiology of CDAD over time and place 
(6). Toxin detection, along with culture, is considered the 
most accurate method of CDAD diagnostics, and it also al-
lows the isolates to be typed in epidemiologic studies.
In Finland, CDAD has not continuously been a notiﬁ  -
able disease. To determine whether the rate of CDAD and 
CDAD-related deaths were increasing in Finland, we ana-
lyzed data from 2 national registers, the hospital discharge 
and death registers, from 1996 through 2004. We also con-
ducted a national survey to evaluate the methods used in 
clinical microbiology laboratories in Finland to diagnose 
infection with C. difﬁ  cile.
Methods
In Finland (population 5.3 million), the national 
healthcare system is organized into 20 geographically and 
administratively deﬁ  ned healthcare districts; populations 
range from 67,800 to 1.7 million. Fifteen healthcare dis-
tricts have only secondary and primary care hospitals, and 
5 also provide tertiary care services.
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Data Sources
The National Hospital Discharge Registry (HILMO) 
contains comprehensive healthcare records on inpatients, 
provided by all hospitals and municipal health centers in 
Finland. Each report to HILMO includes the patient’s na-
tional identity code, admission and discharge dates, health-
care provider, type of service, medical specialty, the place 
(home or institution) from which the patient was trans-
ferred to the facility, and data on surgical procedures and 
discharge diagnoses. HILMO data were used to determine 
the number of discharges with a code speciﬁ  c for CDAD 
from the International Classiﬁ  cation of Diseases, revision 
10 (ICD-10): “enterocolitis due to Clostridium difﬁ  cile” 
(A04.7) and “pseudomembranous enterocolitis associated 
with antimicrobial therapy” (K52.8), listed as the ﬁ  rst or 
any discharge diagnosis. CDAD-related deaths were iden-
tiﬁ  ed from death certiﬁ  cates of the National Population 
Information System in which underlying and immediate 
causes of death and contributory factors are currently coded 
according to ICD-10. In addition, for patients with CDAD 
identiﬁ  ed from HILMO, we obtained death certiﬁ  cate data 
by using the national identity code, and, correspondingly, 
for persons with CDAD identiﬁ  ed from death certiﬁ  cates, 
we obtained their discharge register data in HILMO for the 
preceding year.
Incidence, Mortality Rates, Case-Fatality Rates, and 
Statistical Analysis
Data from the National Population Information Sys-
tem for years 1996–2004 were used as denominators to cal-
culate age- and sex-speciﬁ  c incidence and mortality rates. 
The average annualized incidence rates during the surveil-
lance period in different healthcare districts were calculat-
ed by using the total number of discharges within the total 
population  during 1996–2004. For age standardization, we 
used the European Standard Population as appropriate (7). 
To evaluate secular trends, we calculated the rates for dif-
ferent groups, classiﬁ  ed by age and sex, for each 12-month 
period from January 1996 through December 2004. Pois-
son regression was used to assess whether the observed 
changes in the rates were statistically signiﬁ  cant. We calcu-
lated case-fatality proportions by dividing all deaths due to 
any cause within 30 days after the last CDAD-related dis-
charge, including CDAD-related deaths, by the total num-
ber of patients discharged with a CDAD-related diagnosis. 
Appropriate permissions to use the data from the national 
hospital discharge and death registers were acquired from 
Statistics Finland and the National Research and Develop-
ment Center for Welfare and Health.
Laboratory Survey
In June 2006, we sent a standardized questionnaire to 
32 clinical microbiology laboratories, which represented all 
tertiary (n = 5) and secondary (n = 16) care hospital labo-
ratories and most private laboratories in Finland. The ques-
tionnaire covered different aspects pertaining to CDAD 
diagnosis, such as requests and criteria used for undertak-
ing C. difﬁ  cile investigations, current methods used for the 
diagnosis, and changes in diagnostic procedures during 
1996–2005 as well as the total number of investigations 
that identiﬁ  ed C. difﬁ  cile in 2005.
Results
We found 7,946 and 10,958 discharges from 1996 
through 2004, for which CDAD was listed as either the pri-
mary diagnosis or as any diagnosis, respectively. Among 
8,093 individual patients, 5,239 (65%) were >64 years of 
age and 5,005 (62%) were female. The average annualized 
age-speciﬁ  c incidence rate was >6-fold higher for patients 
>64 years of age than for those 45–64 years of age (108 
vs. 16 hospital discharges/100,000 population). The age-
standardized rate was similar for female and male patients 
(19/100,000 population versus 18/100,000).
Discharges for which CDAD was listed as any diag-
nosis doubled from 810 (16/100,000 population) in 1996 
to 1,787 (34/100,000 population) in 2004 (Figure 1). The 
number of instances in which a patient was given a ﬁ  rst 
diagnosis of CDAD also increased. The increases only 
concerned discharges with code A04.7; the number of dis-
charges with code K52.8 remained at the same level. The 
increase was most prominent for patients >64 years of age, 
from 63/100,000 population to 162/100,000 (Figure 2). A 
slight increase was detected for those 45–64 years of age but 
none for children or those 15–44 years of age. The numbers 
of CDAD-related discharges increased in most healthcare 
districts (80%, 16/20) and in all tertiary care regions (5/5); 
the trend was statistically signiﬁ  cant in 13 of the 20 (65%) 
healthcare districts (p<0.05 by Poisson regression). The 
average annualized age-standardized incidence rates var-
ied greatly between the healthcare districts, from 9/100,000 
population to 28/100,000.
A total of 761 CDAD-related deaths were identiﬁ  ed 
(range by year, 18–143); most (733/761, 96%) occurred 
in persons >64 years. For 81 patients (11%) CDAD was 
considered as the underlying cause of death (range by 
year, 7–13). During 1996–1997, the annual number of 
CDAD-related deaths was ≈20, and thereafter the number 
increased from 70 to a peak of 140. During 1998–2004, 
the age-standardized mortality rate associated with CDAD 
increased from 9 per million population to 17 per million. 
The increase in mortality rate was limited to persons >64 
years of age; during 1998–2004, the age-speciﬁ  c mortality 
rate of CDAD for persons >64 years of age doubled, from 
76 per million population to 146 per million (Figure 3).
Of the 8,402 patients discharged with a CDAD-related 
diagnosis, 1,196 (14.2%) died within 30 days. The overall 
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case-fatality proportion was similar for female and male 
patients (14.1% vs. 14.4%) but varied by age group; the 
case-fatality proportion was highest for patients >64 years 
(20.5%) and lowest for those 15–44 years (0.8%). From 
1996 through 2004, the case-fatality proportion doubled, 
from 7.6% to 15.5%.
Of the 32 clinical microbiology laboratories invited to 
take the survey on diagnostics, 28 laboratories (88%) re-
sponded, including all healthcare districts except 1 (19/20, 
95%). Twenty-four (86%) laboratories, in 18 different 
healthcare districts, reported routinely performing C. dif-
ﬁ  cile diagnostic tests. All laboratories had speciﬁ  c requests 
for C. difﬁ  cile investigation or for investigating cases of 
antimicrobial  drug–associated diarrhea. The methods used 
included toxin detection (88%) and culture (79%); most 
laboratories currently detect both toxins A and B by com-
mercial kits, and 3 detect only toxin A. In 16 laboratories, 
a positive result reported to clinicians was based on both a 
positive culture and a toxin test result; in 5, on a positive 
toxin test result, and in 3, on a positive culture alone. In 
most laboratories, the change from toxin A detection only 
to testing for both toxins A and B occurred after the year 
2000. In 2005, diagnostic sampling activity varied nearly 
10-fold between healthcare districts, from 209 to 1,845 
tests per 100,000 population. The laboratories also had 
wide variation in the proportion of samples positive for C. 
difﬁ  cile (1%–28%), as well as in those positive for toxin 
(range 3%–15%).
Discussion
Our nationwide population-based study shows that 
the rates of CDAD and CDAD-related deaths among el-
derly patients are increasing in Finland. However, on the 
basis of ICD-10 codes, we did not detect an increase in the 
severe form of CDAD, pseudomembranous enterocolitis. 
Although the rates of CDAD and CDAD-related deaths in 
Finland are still lower than the population-based estimates 
reported from the United States (8) and the United Kingdom 
(9), clinicians in Finland were reminded about the increas-
ing risk for CDAD, especially among elderly patients.
A similar population-based study has been performed 
in the United States, where the number of hospital patients 
discharged with CDAD listed as any diagnosis doubled 
from 1996 through 2003 (8). The most pronounced in-
crease occurred during 2000–2003. The US incidence in-
creased to a considerably higher level than that in Finland 
(61 discharges/100,000 population vs. 34/100,000); the US 
increase was several-fold among elderly patients, as in Fin-
land. A difference from our study was that ICD-9 codes 
were in use in the United States during the study period, 
and only code 008.45 (intestinal infection caused by C. 
difﬁ  cile) was analyzed. A doubled rate was also found in 
another US study, which was limited to adults hospitalized 
with CDAD during 2000–2005 (10).
The CDAD-related mortality rate has been evaluated 
in England and Wales using death register data (9). Deaths 
associated with CDAD or pseudomembranous enterocolitis 
more than doubled from an age-standardized mortality rate 
of 11 per million population in 1999 to 24 per million in 
2004. The increase was slightly greater than in Finland dur-
ing the same period (from 9 to 17 per million population ), 
and the mortality rate increased to a somewhat higher level; 
on more than half of the death certiﬁ  cates in England and 
Wales, CDAD was the underlying cause of death. By 2006, 
the mortality rate had further increased by 72% to 64–65 
per million population (11). A similar trend in CDAD-
related mortality rates has also reported from the United 
States during 1999–2004 (12). However, those ﬁ  gures are 
not comparable to ours because the 2000 US population 
was used as a standard.
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Figure 1. Number of hospital discharges with Clostridium difﬁ  cile 
listed as any and primary diagnoses, 1996–2004, Finland. 
International Classiﬁ  cation of Diseases, 10th revision, codes K52.8, 
“pseudomembranous enterocolitis associated with antimicrobial 
drug therapy,” and A04.7, “enterocolitis due to Clostridium difﬁ  cile.”
0
50
100
150
200
1996 1997 1998 1999 2000 2001 2002 2003 2004
D
i
s
c
h
a
r
g
e
s
/
1
0
0
,
0
0
0
 
p
o
p
u
l
a
t
i
o
n
  <15 years
  15–44 years
  45–64 years
  >64 years
Figure 2. Rates of hospital discharges with Clostridium difﬁ  cile 
listed as any diagnosis, by age, 1996–2004, Finland.RESEARCH
In our study, the 30-day case-fatality proportion 
(deaths from all causes) was 14%, which is similar to ﬁ  nd-
ings from other studies that report case-fatality rates rang-
ing from 11% to 25% during hospitalization (3,13–16). 
However, the results are not directly comparable because 
we analyzed the deaths within 30 days after the date of dis-
charge with a CDAD-related diagnosis, not after the date of 
diagnosis, because the latter was not available.
During 1996–2005, considerable changes occurred in 
Finland in the diagnostic methods of C. difﬁ  cile, which may 
have contributed to the increasing rate of CDAD. The re-
gional variation in diagnostic activity may also have had 
an effect. Improvement in CDAD diagnostic procedures 
can still be made, if culture and toxin detection together are 
considered the most accurate method.
Our study, as other register-based studies, has some 
limitations. First, we only analyzed hospital discharge data, 
and the sensitivity and speciﬁ   city of hospital discharge 
coding for CDAD are not well known. In the US study, the 
correlation between toxin assay result and ICD-9 code was 
good: the speciﬁ  city of toxin assay results was excellent 
(99.7%), but the sensitivity was lower (78%) (17). Alter-
natively, it is very unlikely that the sensitivity would have 
remarkably changed during the study period, as stated in 
article about the US study. The validity of Finnish hospital 
discharge and death registers has been assessed only for 
diseases other than CDAD (18,19). The second code we 
used (K52.8, pseudomembranous enterocolitis associated 
with antimicrobial therapy) is not speciﬁ  c for C. difﬁ  cile, 
and its use might have been inconsistent for the severe form 
of CDAD, which is likely to obscure a possibly increas-
ing trend. Second, because the ICD codes were given at 
the time of hospital discharge, we could not assess which 
proportion of CDAD was related to ambulatory healthcare 
or to in-hospital care. In addition, the changes in laboratory 
diagnostics may have inﬂ  uenced the results. A consider-
able proportion of the microbiology laboratories changed 
from using immunoassays that detect only toxin A to using 
assays that detect both toxins A and B. That this would be 
the only reason for the increase in CDAD is unlikely be-
cause only a minor proportion of CDAD (5%) has been re-
ported to be caused by strains producing only toxin B (20). 
No such information is available from Finland. In addition, 
trends in diagnostic activity could not be analyzed because 
the data were available only for 2005.
According to the ﬁ  rst national prevalence survey per-
formed in 2005 in 30 acute care hospitals in Finland, 5% of 
the healthcare-associated infections conﬁ  rmed microbio-
logically were caused by C. difﬁ  cile (21). CDAD was >10× 
more prevalent than infections due to methicillin-resistant 
Staphylococcus aureus. During 1995–1997, ﬁ  ndings posi-
tive for C. difﬁ  cile (positive culture and/or toxin production) 
were included in national laboratory-based surveillance re-
ports in Finland. Because electronic reporting was not yet 
common, surveillance was halted due to the workload and 
difﬁ  culties in interpreting surveillance data because most 
of the positive ﬁ  ndings were based on cultures only.
Our data from this study offer a comprehensive pic-
ture of the trends and the outcome of CDAD in a well-
deﬁ   ned population during the period before the new 
virulent PCR ribotype 027 was detected in Finland. This 
information serves as a point of reference for Finland and 
other industrialized countries when assessing the effects of 
emerging, highly virulent clones on the epidemiology of 
CDAD. Notably, the results we detected in the epidemiol-
ogy of CDAD are similar to those found in limited settings 
in many industrialized countries, even though the rates of 
CDAD and CDAD-related deaths were at a lower level in 
Finland. As elsewhere, the increase in incidence in Finland 
may be due to a growing population at risk, reﬂ  ecting the 
increased prevalence of chronic disease and improved sur-
vival for patients with severe chronic underlying diseases 
as well as increasing use of antimicrobial drugs. The results 
of our study have been used to set up a national surveillance 
system for CDAD, including recommendations for CDAD 
diagnostic procedures.
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Figure 3. Mortality rates associated with Clostridium difﬁ  cile, by 
age, 1996–2004, Finland. Clostridium difﬁ  cile, Finland, 1996–2004
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